Stratos Wealth Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Stratos Wealth Partners’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,500	Closed	-$6K	–	1119
2018 Q3	$6K	Buy	+1,500	New	+$4.7K	﹤0.01%	2366
2018 Q2	–	Sell	-1,500	Closed	-$4K	–	1268
2018 Q1	$4K	Hold	1,500	–	–	﹤0.01%	2667
2017 Q4	$6K	Buy	+1,500	New	+$4.96K	﹤0.01%	2320

Other funds holding CPRX

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Stratos Wealth Partners's CPRX Position: Q4 2018 in Review

Stratos Wealth Partners sold out of Catalyst Pharmaceutical (CPRX) in Q4 2018, closing a stake of 1,500 shares — an estimated $6K sold.

Stratos Wealth Partners first reported a position in CPRX in Q4 2017 and held it in 3 quarters. The position peaked at $6K in Q3 2018. 86 funds tracked by Wall St. Rank hold CPRX as of Q4 2018.

Stratos Wealth Partners reported no remaining Catalyst Pharmaceutical position as of Q4 2018 after selling out during the quarter.
Stratos Wealth Partners sold 1,500 Catalyst Pharmaceutical shares in Q4 2018, an estimated $6K.
Stratos Wealth Partners first reported a position in Catalyst Pharmaceutical in Q4 2017 and held it in 3 quarters.
Stratos Wealth Partners's Catalyst Pharmaceutical position peaked at $6K in Q3 2018.
86 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2018.

Based on Stratos Wealth Partners's 13F filing for Q4 2018, filed 8 Feb 2019.